Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

@article{Baldwin2014EvidencebasedPT,
  title={Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology},
  author={David S. Baldwin and Ian M. Anderson and David J. Nutt and Christer Allgulander and Borwin Bandelow and Johan A. den Boer and David M. Christmas and Simon J C Davies and Naomi Anne Fineberg and Nicky Lidbetter and Andrea L. Malizia and Paul McCrone and Daniel Joseph Nunes Nabarro and Catherine O'Neill and Jan Scott and Nic J. A. Van der Wee and Hans-Ulrich Wittchen},
  journal={Journal of Psychopharmacology},
  year={2014},
  volume={28},
  pages={403 - 439}
}
This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas… Expand

Paper Mentions

Interventional Clinical Trial
The primary study objective is to determine the efficacy of pregabalin administered orally for a period of 12 weeks in reducing risky drinking and symptoms of posttraumatic stress… Expand
ConditionsAlcohol Use Disorder, PTSD
InterventionDrug, Other
Pharmacological treatment of obsessive compulsive disorder in adults: A clinical practice guideline based on the ADAPTE methodology.
TLDR
This article summarises the process of preparing this guideline and the recommendations adopted by consensus by a guideline panel grouped into five areas of interest: acute treatment, duration of treatment, predictors of response and special symptoms, partial response to lack of response to treatment, and special populations. Expand
Pharmacological treatment of obsessive compulsive disorder in adults: A clinical practice guideline based on the ADAPTE methodology.
TLDR
This article summarises the process of preparing this guideline and the recommendations adopted by consensus by a guideline panel grouped into five areas of interest: acute treatment, duration of treatment, predictors of response and special symptoms, partial response to lack of response to treatment, and special populations. Expand
Obsessive–compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults
TLDR
Robust data supports the effectiveness of treatment with selective serotonin reuptake inhibitors (SSRIs) and clomipramine in the short-term and the longer-term treatment and for relapse prevention. Expand
Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
TLDR
The British Association for Psychopharmacology guidelines specify the scope and targets of treatment for bipolar disorder, and recommend strategies for the use of medicines in short-term treatment of episodes, relapse prevention and stopping treatment. Expand
Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review
TLDR
Evidence that only a few AAs are effective in only a minority of the off-label conditions in which they are currently used is supported and confirms that AAs should be on the basis of a balance between efficacy and side effects and the characteristics as well as the preference of the patient. Expand
Pharmacologic Treatment for Trauma-Related Psychological Disorders
TLDR
This chapter discusses the pharmacological treatments for PTSD; however, many of these principles apply to the treatment of depression, anxiety, and sleep problems associated with the broader trauma-related disorders. Expand
Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders
TLDR
The article presents those selected therapeutic advances judged to be of utmost relevance to the treatment of OCD, based on new and emerging evidence from clinical and translational science. Expand
The German guidelines for the treatment of anxiety disorders
A consensus group consisting of 36 experts representing 20 leading German specialist societies and patient self-help organizations developed evidence-based recommendations for the treatment ofExpand
Treatment of posttraumatic stress disorder: Focus on pharmacotherapy
  • M. Ehret
  • Medicine
  • The mental health clinician
  • 2019
TLDR
When selecting an appropriate medication for a patient diagnosed with posttraumatic stress disorder, the clinician needs to consider the current symptomatology being experienced, comorbid conditions, and evidence for efficacy of specific treatments prior to initiating medications. Expand
Management of Treatment-Resistant Posttraumatic Stress Disorder
TLDR
Comprehensive assessment of TRPTSD, including a thorough evaluation of associated comorbidity, should inform individualized care, incorporating a process of shared decision-making. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 598 REFERENCES
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
TLDR
These British Association for Psychopharmacology guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments. Expand
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
TLDR
These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse, and stopping treatment. Expand
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines
A revision of the British Association for Psychopharmacology guidelines for treating depressive disorders with antidepressants was undertaken in order to specify the scope and target of theExpand
Evidence-Based Guidelines for Treating Bipolar Disorder: Recommendations from the British Association for Psychopharmacology
  • G. Goodwin
  • Medicine
  • Journal of psychopharmacology
  • 2003
TLDR
The guidelines cover the diagnosis of bipolar disorder, clinical management and strategies for the use of medicines in short-term treatment of episodes, relapse prevention and stopping treatment. Expand
BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
TLDR
The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people. Expand
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
  • T. Barnes
  • Medicine
  • Journal of psychopharmacology
  • 2011
TLDR
These guidelines from the British Association for Psychopharmacology address the scope and targets of pharmacological treatment for schizophrenia, and cover the pharmacological management and treatment of schizophrenia across the various stages of the illness. Expand
Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology
TLDR
These guidelines primarily cover the pharmacological management of withdrawal, shortand longterm substitution, maintenance of abstinence and prevention of complications, where appropriate, in substance misuse, addiction and comorbidity with psychiatric disorders. Expand
Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD).
  • J. Ipser, Dan J Stein
  • Psychology, Medicine
  • The international journal of neuropsychopharmacology
  • 2012
TLDR
The largest body of evidence for short- and long-term efficacy of medication currently exists for SSRIs, with promising initial findings for the selective noradrenergic reuptake inhibitor venlafaxine and the atypical antipsychotic risperidone. Expand
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
  • B. Bandelow, J. Zohar, E. Hollander, S. Kasper, H. Möller, WFSBP TASK FORCE ON TREATMENT GUIDELINES FOR ANXIE
  • Psychology, Medicine
  • The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2008
TLDR
Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines. Expand
The evidence-based pharmacotherapy of social anxiety disorder.
TLDR
Cognitive-behavioural is a well-established alternative first line therapy that may also be a helpful adjunct in non-responders to pharmacological treatment of SAD. Expand
...
1
2
3
4
5
...